Harsini Harsini
Universitas Sebelas Maret

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

The Relationship of Interferon Gamma +874T/A and Interleukin-10 -1082G/A Gene Polymorphism to The Recovery of Multidrug Resistant Tuberculosis Patients Ita Haryatie; Harsini Harsini; Reviono Reviono
Jurnal Respirologi Indonesia Vol 37, No 4 (2017)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (551.503 KB) | DOI: 10.36497/jri.v37i4.85

Abstract

Background: Multidrug resistant (MDR) TB caused by the M.Tb strain is resistant toward at least rifampicin and isoniazid. Interferon Gamma is responsible for activating macrophages and phagocytosis for M.Tb destruction. Interleukin 10 causes a significant decrease in reactive nitrogen intermediates, increased arginase 1, and overall decreased macrophage function. Gene mutation causes IFN production by CD4 - T cells less effective and disrupts the immune response against M.Tb. There has been no research on the relationship between IFN-γ and IL-10 gene polymorphisms with TB recovery in Indonesia, especially in patients with MDR-TB. The aim of this study is to determine gene polymorphism relationship of IFN-γ +874T/A and IL-10 -1082G/A with MDR-TB recovery. Methods: This study was a non-experimental clinical trial with a retrospective cohort design. The study was conducted on 105 MDR-TB patients treated in dr. Moewardi Hospital between January 2011-June 2014 consists of 84 recovered patients and 21 patients died/failed. Results: Gene polymorphism of IFN-γ +874T/A was obtained OR=0.703 (0.265-1.863) and P=0.477 which mean IFN-γ +874 T/A gene was not related to recovered case of MDR-TB. The IL-10 -1082G/A gene obtained the value of OR=0.657 (0.173-2.491) and the value P=0.785 which means that IL-10 -1082G/A is not related to the MDR-TB case recovery. Conclusions: There is no relationship of IFN-γ + 874T/A and IL-10 -1082G/A gene polymorphisms in the recovery of MDR-TB patients. (J Respir Indo. 2017; 37(4): 299-306)
Effect Of Nigella sativa Cement Extract on Procalcitonin, TNF-α Level and Time to Clinical Stable in Pneumonia Patients Lusiana Susilo Utami; Reviono Reviono; Suradi Suradi; Harsini Harsini; Jatu Aphridasari
Jurnal Respirologi Indonesia Vol 37, No 4 (2017)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (651.138 KB) | DOI: 10.36497/jri.v37i4.87

Abstract

Background: Pneumonia is an infectious disease with highest morbidity and mortality in the world. The research objectives is to determine the effect of Nigella sativa cement extract in procalcitonin, TNF-α levels, and clinical improvement in pneumonia patients. Methods: This study is a clinical trial quasi experimental design with pre and post test approach in the treatment group and the comparison group. Samples were taken by consecutive sampling between April and May 2016 a total of 30 patients were divided into 2 groups:the treatment group and the comparison group. The treatment group was given additional therapy capsules Nigella sativa cement extract, the comparison group was given the standard therapy. Procalcitonin levels and TNF-α is checked when the patient was admitted and when clinical improvement is achieved. Results: Decreased levels of procalcitonin in the treatment group (8.969±13.591 ng/dl) and a comparison group (1.907±6293 ng/dl) was statistically significant (p= 0.014; 95 % CI= 0.222-1.770). Decreased levels of TNF-α was not significantly different between treatment groups (58.759(1.840-166.50) pg/dl) and a comparison group (57.485 (35.410-81.650) pg/dl), with p= 0.395. The achievement of clinical improvement in the treatment group 4.60±8.28 days and the comparison group 5.53 ±1.45 today, statistically no difference between the two groups. Conclusion: Capsule Nigella sativa cement extract provides benefit for declining levels of procalcitonin and accelerate achievement of clinically stable in pneumonia patients. (J Respir Indo. 2017; 37(4): 316-24)